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Aim of the study: Genetic (idiopathic) generalized epilepsies (GGEs) account for nearly
one-third of all epilepsies. The frequency of status epilepticus (SE) in patients with GGEs
has been poorly studied. Therefore, this study aimed to evaluate the frequency of different
forms of SE in a cohort of patients with GGEs.
Materials and methods: Among 153 patients with GGEs treated at the university epilepsy
clinic in the period between 1998 and 2018, those with SE were retrospectively identified.
Results: Absence SE was diagnosed in 8 patients (13 episodes), while myoclonic SE was
found in 2 patients (2 episodes). No cases of tonic–clonic SE were detected in the study
cohort. Most SE episodes were found to be provoked by ill-advised antiepileptic drugs or
changes in drug regimen. In all the subjects, SE was stopped by intravenous administration
of diazepam and/or valproate. Long-term outcome of epilepsy was good, with most patients
(70%) being seizure-free.
Conclusion: Status epilepticus is not a rare phenomenon in patients with genetic general-
ized epilepsies, with absence SE being the most common type. Most cases of SE are
provoked by ill-advised AEDs or changes in drug regimen. Status epilepticus in GGEs can
be easily treated with benozdiazepines and/or valproate. Status epilepticus in GGEs can be
easily treated with benozdiazepines and/or valproate.
Keywords: absence status epilepticus, myoclonic status epilepticus, genetic generalized
epilepsy
Introduction
Genetic (idiopathic) generalized epilepsies (GGEs) are a well-recognized
subgroup of generalized epilepsy with a presumed genetic etiology. They
comprise 15–20% of all epilepsies.1,2 GGEs are characterized by different
combinations of generalized seizures such as absence, myoclonic, and gener-
alized tonic–clonic and generalized epileptiform discharges on electroence-
phalography (EEG). Childhood absence epilepsy, juvenile absence epilepsy,
juvenile myoclonic epilepsy, and epilepsy with generalized tonic–clonic sei-
zures alone are well-characterized syndromes of GGEs.3 The frequency of
status epilepticus (SE) in patients with GGEs has been poorly studied,4 with
most studies on SE being case reports or case series. In a recent, population-
based study, no cases of typical absence or myoclonic SE were found;5 in
a cohort, hospital-based study, absence SE was found to account for <1% of
cases, while no episodes of myoclonic SE were identified.6 The aim of this
study was to evaluate the frequency of different forms of SE in a cohort of
patients with GGEs.
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Materials and methods
This was a retrospective cohort study conducted at the
Epilepsy Clinic at Jagiellonian University, Krakow,
Poland. Patients with GGEs who had been observed and
clinically managed in the clinic in the period between
1998 and 2018 were identified from the electronic data-
base and included in the study. The following information
was collected from the patients using a structured ques-
tionnaire: age, sex, age at the diagnosis of epilepsy, dura-
tion of epilepsy, seizure types, family history of epilepsy,
and findings of EEG and neuroradiology. Inclusion criteria
were as follows: combination of generalized seizure types
(absence, myoclonic, and/or generalized tonic–clonic),
generalized spike/polyspike and wave discharges with nor-
mal background activity on interictal EEG, and normal
magnetic resonance imaging. Syndromes of GGEs in
patients were classified according to the classification
scheme proposed by the International League Against
Epilepsy.7 Three patients with Jeavons syndrome were
also included in the study. Among the included patients,
those with adequately documented episodes of SE were
retrospectively identified. In these patients, SE was classi-
fied according to a classification system recently proposed
by the International League Against Epilepsy.8 The clin-
ical and EEG data of all identified SE episodes were
analyzed. The study was conducted in compliance with
Declaration of Helsinki and was reviewed and approved
by the bioethics committee of the university
(122.6120.32.2017 issued 22 Feb 2017). Patients' consent
was not required by the bioethics committee as it was
a retrospective chart review. Patients' personal data were
available only to the senior author who is the treating
physician and anonymized before statistical analysis.
Results
Cohort characteristics
The study population consisted of 153 patients (including
106 women; 69.3%); 13.5% of 1132 patients were treated
in the clinic during the study period. The mean age of the
patients at the time of inclusion in the study was 31.6 years
(SD ±9.8), and the mean age at the onset of epilepsy was
15.6 years (SD ±5.6). The mean duration of follow-up of
the cohort members was 9.3 years (SD ±5.2, range 1–20
years). Juvenile myoclonic epilepsy was the most common
syndrome observed among patients (74; 48.4%), followed
by epilepsy with generalized tonic–clonic seizures alone
(43; 28.1%) and juvenile absence epilepsy (29; 18.9%).
Childhood absence epilepsy was diagnosed in 4 (2.7%)
patients and Jeavons syndrome in 3 (1.9%) patients.
Status epilepticus
A total of 10 (8 female) patients (6,5% of the cohort) with
15 episodes of SE were identified. Absence SE was diag-
nosed in 8 patients (13 episodes) and myoclonic SE in 2
patients (2 episodes). Tonic–clonic SE was not found in
any patient. All patients developed only one type of SE,
either absence or myoclonic. The clinical characteristics of
the subjects and the episodes of SE are summarized in
Table 1.
The cardinal clinical features of absence SE were con-
fusion (to different extent), slowing, and difficulties in
performing daily activities. Patient 7 had simple gestural
automatisms. Patients with myoclonic SE presented with
repetitive myoclonic jerks of the upper limbs and slight
disorientation. The episode of SE preceded diagnosis of
epilepsy in 2 patients (Patients 7 and 9), whereas in 1
patient (Patient 1) SE occurred after long-term remission
off medication. In 3 subjects, absence SE was either fol-
lowed by (Patients 1 and 5) or interspersed with (Patient 8)
a generalized tonic–clonic seizure. In 4 cases, SE was
precipitated by contraindicated drugs (carbamazepine, tia-
gabine, gabapentin, and/or vigabatrin); these patients were
referred to the Department of Neurology with the diagno-
sis of pharmacoresistant focal epilepsy with seizure aggra-
vation. The approximate duration of SE episodes varied
from 30 mins to 48 hrs.
EEG data during SE were available for all but 1
patient; in the case of Patients 7 and 8, EEG data were
available for 1 episode for each. Video-EEG was available
for 4 subjects. In patients who took ill-advised drugs, EEG
showed bilateral bursts or continuous discharges of sharp
and/or slow waves of 2–4 Hz (Figure 1). In the remaining
patients, EEG showed generalized spikes/polyspikes and
slow-wave discharges of >2.5 Hz (Figure 2). EEG samples
of the remaining patients with absence status epilepticus
are presented in supplementary materials (Figures S1–S5).
In all the cases, SE was stopped by intravenous admin-
istration of diazepam and/or valproate. Long-term out-
come of epilepsy was found to be good, with most
patients (70%) being seizure-free. Long-term treatment
included broad-spectrum AEDs: VPA, LTG, and/or LEV.
Discussion
In this long-term, retrospective study, a total of 15 epi-
sodes of SE were identified in 6.5% (10 patients) of the
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cohort, with 15 episodes per 1428 patient-years. The rate
of episodes was much lower than that found in the study of
Agathonikou et al (15.4%).9 However, their study com-
prised patients with syndromes characterized by a high
frequency of SE, namely perioral myoclonia with absences
and idiopathic generalized epilepsy with phantom
absences.10 In contrast, in the present study, two-thirds of
the subjects with SE suffered from juvenile absence
epilepsy.
It was found that in 40% of patients, SE was provoked
by ill-advised antiepileptic drugs (AEDs); the phenomenon
of paradoxical aggravation of epilepsy is well known in
GGEs.11,12 In this group of patients, ictal EEG findings
were inconsistent with GGEs, most probably due to con-
traindicated treatment. In the opinion of the authors,
knowledge and awareness about the subtypes of GGEs
should be increased, as the correct classification of syn-
drome is indispensable for choosing the appropriate
Table 1 Clinical characteristics of patients and the episodes of SE
Case
(sex, age)
GGE syndrome
(age of onset in
years, type or
first seizure)
Type of SE
(approximate
duration)
Cause of SE AEDs treat-
ment at SE
Treatment
of SE
Outcome and
follow-up
(years)
1.M, 39 JAE (11, AS) Absence status epi-
lepticus (24 hrs)
Relapse after
seziure-free per-
iod off medication
None Diazepam iv Seizure-free on VPA
1000 mg (4)
2.M, 66 JAE (11, AS) Absence status epi-
lepticus (6 hrs)
VPA tapering due
to side effects
VPA 300 mg/
LTG 300 mg
Diazepam iv,
VPA iv
Seizure-free on VPA
1000 mg, LTG
200 mg (2)
3.F, 30 JAE (15, AS) Absence status epi-
lepticus (5 hrs)
Ill-advised AEDs TGB 30 mg/
CBZ 800 mg
Diazepam iv Seizure-free on VPA
600 mg (10)
4.F, 34 GTCSA (17, TCS) Absence status epi-
lepticus (8 hrs)
Ill-advised AEDs CBZ 1600 mg/
VGB 2000 mg
VPA iv Seizure-free on VPA
2000 mg (3)
5.F, 70 JAE (16, AS) Absence status epi-
lepticus
(12 hrs)
AEDs missed for
3 days
LTG 300 mg Diazepam iv,
VPA iv
LTG 300 mg/VPA
600 mg at discharge,
lost to follow-up
6.F, 42 JAE (17, AS) Absence status epi-
lepticus (48 hrs)
Ill-advised AEDs CBZ 1600 mg/
GBP 3600 mg/
TPM 800 mg
Diazepam, iv,
VPA iv
Seizure-free on
VPA600 mg/LTG
400 mg (4)
7. F, 31 JAE (11, AS) Absence status epi-
lepticus – 5 episodes
(30–180 mins)
1 episode related
to infection with
fever
LTG 200 mg Diazepam iv Infrequent AS on
LTG 500 mg (1)
8. F,
28 at first epi-
sode.
35 at second
episode
JAE (15, AS) Absence status epi-
lepticus
First episode
(7 hrs)
Second episode
(60 mins)
Before diagnosis,
sleep deprivation
Adding hormonal
contraception to
LTG
None
LTG 100 mg
Diazepam iv
Diazepam iv
Infrequent AS on
LTG 200 mg (4)
9.F, 26 JME (TCS, 21) Myoclonic status
epilepticus (3 hrs)
Ill-advised AEDs GBP 3600 mg/
VGB 1000 mg
Diazepam iv Seizure-free on VPA
600 mg/LEV
2000 mg (16)
10. F, 20 JME (MS, 14) Myoclonic status
epilepticus (2 hrs)
Sleep deprivation,
alcohol
None Diazepam iv Seizure-free on LEV
1000 mg (6)
Abbreviations: SE, status epilepticus; JAE, juvenile absence epilepsy; JME, juvenile myoclonic epilepsy; GTCSA, generalized tonic–clonic seizures alone; AEDs, antiepeilptic
drugs; AS, absence seizures; MS, myoclonic seizures; TCS, tonic-clonic seizures; CBZ, carbamazepine; GBP, gabapentin; LTG, lamotrigine; TGB, tiagabine; TPM, topiramate;
VGB, vigabatrin; VPA, valproate; iv, intravenous.
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treatment. In further 30% of patients, SE episode was
caused due to lowering the dose of AEDs.
In Patient 7 with recurrent, mostly unprovoked, episodes
of absence SE, absence status epilepsy was suspected.13
This study provided reassuring findings related to the
prevalence of generalized convulsive SE in patients with
GGEs; no cases of generalized convulsive SE were found
in the study cohort.
We acknowledge some limitations of this study.
Firstly, due to its retrospective design, some cases of
SE could have been missed. Especially episodes of
absence SE may have gone unrecognized. Secondly,
Figure 1 Absence status epilepticus in patient 6. Vertical bar - 100uV, horizontal bar- 1 sec.
Figure 2 Absence status epilepticus in patient 1. Vertical bar - 100uV, horizinatl bar - 1 sec.
Bosak et al Dovepress
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the number of patients in our cohort was relatively
small. Thirdly, we included only adult patients, while
the frequency of GGEs is higher in children/adolescents.
Conclusion
SE is not a rare phenomenon in patients with genetic general-
ized epilepsies, with absence SE being the most common type.
This study found that most cases of SE were provoked by ill-
advised AEDs or changes in drug regimen. Appropriate treat-
ment of GGEs with broad-spectrum AEDs (VPA, LTG, LEV,
TPM) is indispensable for preventing SE episodes. EEG is
crucial in the diagnosis of absence SE; however, it may not
show classical generalized spikes/polyspikes and slow-wave
discharges of >2.5 Hz in patients treated with contraindicated
AEDs. Episodes of SE are an easily treatable complication of
GGEs.
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Supplementary materials
Figure S1 Absence status epilepticus in patient 2. Vertical bar - 100uV, horizontal bar - 1 sec.
Figure S2 Absence status epilepticus in patient 3. Vertical bar - 100uV, horizontal bar - 1 sec.
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Figure S3 Absence status epilepticus in patient 4. Vertical bar - 100uV, horozontal bar - 1 sec.
Figure S4 Absence status epilepticus in patient 5. Vertical bar - 100uV, horizontal bar - 1 sec.
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